DOST begins ‘mix and match’ vaccine clinical study
MANILA, Philippines — The COVID-19 vaccine “mix and match” clinical study of the Department of Science and Technology (DOST) started in Muntinlupa City on Monday.
Rowena Guevara, undersecretary for research and development of DOST, said the first dry run of the clinical trials was held in Marikina City on Oct. 18, followed by the cities of Muntinlupa and Davao on Oct. 25 and Oct. 29.
The Food and Drug Administration approved on Nov. 19 the mix and match trials to evaluate the safety and immunogenicity of completing the vaccination with different brands and platforms.
The Philippine Society for Allergy, Asthma and Immunology is leading the study.
The DOST is eyeing 3,000 participants who must be 18 years of age, have no history of confirmed COVID-19 infection, have not received any vaccine previously, relatively healthy and have an account with Philippine Health Insurance Corp.
